UBS Group Begins Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)

Investment analysts at UBS Group began coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) in a research report issued on Monday, The Fly reports. The firm set a “neutral” rating on the stock.

TEVA has been the subject of several other research reports. Piper Sandler cut Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and decreased their target price for the stock from $11.00 to $7.00 in a research note on Wednesday, May 4th. Barclays upgraded Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $11.00 to $13.00 in a report on Tuesday, April 5th. Sanford C. Bernstein upgraded Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $11.00 price target on the stock in a report on Friday, March 25th. Bank of America upgraded Teva Pharmaceutical Industries from an “underperform” rating to a “neutral” rating and set a $9.00 price target on the stock in a report on Tuesday, May 17th. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Monday, June 6th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.83.

NYSE TEVA traded down $0.43 during trading hours on Monday, hitting $7.89. 10,502,500 shares of the company’s stock were exchanged, compared to its average volume of 8,890,879. The stock has a 50-day simple moving average of $8.93 and a 200 day simple moving average of $8.56. Teva Pharmaceutical Industries has a 1-year low of $7.23 and a 1-year high of $11.20. The firm has a market cap of $8.71 billion, a price-to-earnings ratio of -14.35, a PEG ratio of 1.04 and a beta of 1.17. The company has a current ratio of 1.07, a quick ratio of 0.73 and a debt-to-equity ratio of 2.03.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last released its earnings results on Tuesday, May 3rd. The company reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55. Teva Pharmaceutical Industries had a positive return on equity of 24.04% and a negative net margin of 3.95%. The business had revenue of $3.66 billion during the quarter, compared to analysts’ expectations of $3.75 billion. During the same quarter last year, the firm posted $0.60 earnings per share. The firm’s revenue was down 8.1% on a year-over-year basis. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.39 earnings per share for the current fiscal year.

In other news, VP Hafrun Fridriksdottir sold 130,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 17th. The stock was sold at an average price of $8.22, for a total value of $1,068,600.00. Following the transaction, the vice president now owns 1,387 shares in the company, valued at $11,401.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.82% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the company. Fieldpoint Private Securities LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 100,000.0% in the first quarter. Fieldpoint Private Securities LLC now owns 3,003 shares of the company’s stock valued at $28,000 after purchasing an additional 3,000 shares in the last quarter. Koshinski Asset Management Inc. lifted its holdings in Teva Pharmaceutical Industries by 61.6% during the fourth quarter. Koshinski Asset Management Inc. now owns 3,934 shares of the company’s stock worth $32,000 after acquiring an additional 1,500 shares during the period. Kistler Tiffany Companies LLC lifted its holdings in Teva Pharmaceutical Industries by 932.2% during the fourth quarter. Kistler Tiffany Companies LLC now owns 4,139 shares of the company’s stock worth $33,000 after acquiring an additional 3,738 shares during the period. Huntington National Bank lifted its holdings in Teva Pharmaceutical Industries by 115.7% during the fourth quarter. Huntington National Bank now owns 4,850 shares of the company’s stock worth $38,000 after acquiring an additional 2,601 shares during the period. Finally, Future Financial Wealth Managment LLC bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $49,000. Institutional investors own 45.79% of the company’s stock.

Teva Pharmaceutical Industries Company Profile (Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Featured Stories

The Fly logo

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.